A novel vaccination strategy mediating the induction of lung-resident memory CD8 T cells confers heterosubtypic immunity against future pandemic influenza virus

Journal of Immunology

Volumn 196, Issue 6, 2016, Pages 2637-2645

  Lee, Yu Na ^a   Lee, Young Tae ^a   Kim, Min Chul ^a,b   Gewirtz, Andrew T ^a   Kang, Sang Moo ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b Animal Plant and Fisheries Quarantine and Inspection Agency   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CD103 ANTIGEN; CD69 ANTIGEN; EPITOPE; GAMMA INTERFERON; INFLUENZA VACCINE; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CYTOKINE RELEASE; FEMALE; INFLUENZA A VIRUS; LUNG; MEMORY T LYMPHOCYTE; MOUSE; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; PROTEIN DOMAIN; SECONDARY INFECTION; TANDEM REPEAT; VACCINATION; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS STRAIN; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CROSS REACTION; HUMAN; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; INFLUENZA, HUMAN; LYMPHOCYTE ACTIVATION; MASS IMMUNIZATION; METABOLISM; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMIC; PROCEDURES; VIRION; VIROLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; FEMALE; HUMANS; IMMUNODOMINANT EPITOPES; IMMUNOLOGIC MEMORY; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERFERON-GAMMA; LUNG; LYMPHOCYTE ACTIVATION; MASS VACCINATION; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE; ORTHOMYXOVIRIDAE INFECTIONS; PANDEMICS; VIRAL MATRIX PROTEINS; VIRION;

EID: 84962583875     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1501637     Document Type: Article

References (53)

1. Zambon, M., and C. W. Potter. 2009. Influenza. In Principles and Practice of Clinical Virology, 6th ed. A. J. Zuckerman, J. E. Banatvala, B. D. Schoub, P. D. Griffiths, and P. Mortimer, eds. John Wiley & Sons, Chichester, U. K.
2. Webster, R. G., and W. G. Laver. 1972. The origin of pandemic influenza. Bull. World Health Organ. 47:449-452.
3. Palese, P. 2004. Influenza: old and new threats. Nat. Med. 10 (12, Suppl):S82-S87.
4. Centers for Disease Control and Prevention. 2010. 2009 H1N1 Flu: International Situation Update. Centers for Disease Control and Prevention, Atlanta.
5. Garten, R. J., C. T. Davis, C. A. Russell, B. Shu, S. Lindstrom, A. Balish, W. M. Sessions, X. Xu, E. Skepner, V. Deyde, et al. 2009. Antigenic and genetic characteristics of swine-origin 2009 A (H1N1) influenza viruses circulating in humans. Science 325:197-201.
6. Grebe, K. M., J. W. Yewdell, and J. R. Bennink. 2008. Heterosubtypic immunity to influenza A virus: where do we stand? Microbes Infect. 10:1024-1029.
7. Kreijtz, J. H., R. Bodewes, G. Van Amerongen, T. Kuiken, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2007. Primary influenza A virus infection induces cross-protective immunity against a lethal infection with a heterosubtypic virus strain in mice. Vaccine 25:612-620.
8. Laurie, K. L., L. A. Carolan, D. Middleton, S. Lowther, A. Kelso, and I. G. Barr. 2010. Multiple infections with seasonal influenza Avirus induce cross-protective immunity against A (H1N1) pandemic influenza virus in a ferret model. J. Infect. Dis. 202:1011-1020.
9. Yetter, R. A., W. H. Barber, and P. A. Small, Jr. 1980. Heterotypic immunity to influenza in ferrets. Infect. Immun. 29:650-653.
10. Cowling, B. J., S. Ng, E. S. Ma, C. K. Cheng, W. Wai, V. J. Fang, K. H. Chan, D. K. Ip, S. S. Chiu, J. S. Peiris, and G. M. Leung. 2010. Protective efficacy of seasonal influenza vaccination against seasonal and pandemic influenza virus infection during 2009 in Hong Kong. Clin. Infect. Dis. 51:1370-1379.
11. Epstein, S. L. 2006. Prior H1N1 influenza infection and susceptibility of Cleveland Family Study participants during the H2N2 pandemic of 1957: an experiment of nature. J. Infect. Dis. 193:49-53.
12. McCaw, J. M., J. McVernon, E. S. McBryde, and J. D. Mathews. 2009. Influenza: accounting for prior immunity. Science 325:1071, author reply 1072-1073.
13. Rimmelzwaan, G. F., R. A. Fouchier, and A. D. Osterhaus. 2007. Influenza virusspecific cytotoxic T lymphocytes: a correlate of protection and a basis for vaccine development. Curr. Opin. Biotechnol. 18:529-536.
14. Bodewes, R., J. H. Kreijtz, C. Baas, M. M. Geelhoed-Mieras, G. De Mutsert, G. Van Amerongen, J. M. Van Den Brand, R. A. Fouchier, A. D. Osterhaus, and G. F. Rimmelzwaan. 2009. Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS One 4:e5538.
15. + T-cell responses in mice. J. Gen. Virol. 91:1743-1753.
16. Schotsaert, M., T. Ysenbaert, K. Neyt, L. I. Ibañez, P. Bogaert, B. Schepens, B. N. Lambrecht, W. Fiers, and X. Saelens. 2013. Natural and long-lasting cellular immune responses against influenza in the M2e-immune host. Mucosal Immunol. 6:276-287.
17. Ito, T., O. T. Gorman, Y. Kawaoka, W. J. Bean, and R. G. Webster. 1991. Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins. J. Virol. 65:5491-5498.
18. Zebedee, S. L., and R. A. Lamb. 1989. Nucleotide sequences of influenza Avirus RNA segment 7: a comparison of five isolates. Nucleic Acids Res. 17:2870.
19. Fiers, W., M. De Filette, A. Birkett, S. Neirynck, and W. Min Jou. 2004. A "universal" human influenza A vaccine. Virus Res. 103:173-176.
20. Du, L., Y. Zhou, and S. Jiang. 2010. Research and development of universal influenza vaccines. Microbes Infect. 12:280-286.
21. Zhao, G., Y. Lin, L. Du, J. Guan, S. Sun, H. Sui, Z. Kou, C. C. Chan, Y. Guo, S. Jiang, et al. 2010. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol. J. 7:9.
22. Kim, M. C., J. M. Song, E. O, Y. M. Kwon, Y. J. Lee, R. W. Compans, and S. M. Kang. 2013. Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus. Mol. Ther. 21:485-492.
23. Song, J. M., J. Hossain, D. G. Yoo, A. S. Lipatov, C. T. Davis, F. S. Quan, L. M. Chen, R. J. Hogan, R. O. Donis, R. W. Compans, and S. M. Kang. 2010. Protective immunity against H5N1 influenza virus by a single dose vaccination with virus-like particles. Virology 405:165-175.
24. Quan, F. S., R. W. Compans, H. H. Nguyen, and S. M. Kang. 2008. Induction of heterosubtypic immunity to influenza virus by intranasal immunization. J. Virol. 82:1350-1359.
25. Song, J. M., B. Z. Wang, K. M. Park, N. Van Rooijen, F. S. Quan, M. C. Kim, H. T. Jin, A. Pekosz, R. W. Compans, and S. M. Kang. 2011. Influenza virus-like particles containing M2 induce broadly cross protective immunity. PLoS One 6:e14538.
26. Wakamiya, N., Y. Okuno, F. Sasao, S. Ueda, K. Yoshimatsu, M. Naiki, and T. Kurimura. 1992. Isolation and characterization of conglutinin as an influenza A virus inhibitor. Biochem. Biophys. Res. Commun. 187:1270-1278.
27. Dundon, W. G., P. De Benedictis, E. Viale, and I. Capua. 2010. Serologic evidence of pandemic (H1N1) 2009 infection in dogs, Italy. Emerg. Infect. Dis. 16:2019-2021.
28. Lee, Y. N., H. J. Lee, D. H. Lee, J. H. Kim, H. M. Park, S. S. Nahm, J. B. Lee, S. Y. Park, I. S. Choi, and C. S. Song. 2011. Severe canine influenza in dogs correlates with hyperchemokinemia and high viral load. Virology 417:57-63.
29. Reed, L. J., and H. Muench. 1938. A simple method for estimating fifty percent endpoints. Am. J. Epidemiol. 27:493-497.
30. + T cells for long-term pulmonary protection against influenza. Eur. J. Immunol. 36:770-778.
31. + T cells. Eur. J. Immunol. 34:3091-3101.
32. Massa, C., and B. Seliger. 2013. Fast dendritic cells stimulated with alternative maturation mixtures induce polyfunctional and long-lasting activation of innate and adaptive effector cells with tumor-killing capabilities. J. Immunol. 190:3328-3337.
33. Mishra, S., P. T. Losikoff, A. A. Self, F. Terry, M. T. Ardito, R. Tassone, W. D. Martin, A. S. De Groot, and S. H. Gregory. 2014. Peptide-pulsed dendritic cells induce the hepatitis C viral epitope-specific responses of naïve human T cells. Vaccine 32:3285-3292.
34. Jegerlehner, A., N. Schmitz, T. Storni, and M. F. Bachmann. 2004. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 172:5598-5605.
35. Treanor, J. J., E. L. Tierney, S. L. Zebedee, R. A. Lamb, and B. R. Murphy. 1990. Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice. J. Virol. 64:1375-1377.
36. Mozdzanowska, K., K. Maiese, M. Furchner, and W. Gerhard. 1999. Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection. Virology 254:138-146.
37. Lee, Y. N., Y. T. Lee, M. C. Kim, H. S. Hwang, J. S. Lee, K. H. Kim, and S. M. Kang. 2014. Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination. Immunology 143:300-309.
38. Turner, D. L., K. L. Bickham, J. J. Thome, C. Y. Kim, F. D'Ovidio, E. J. Wherry, and D. L. Farber. 2014. Lung niches for the generation and maintenance of tissue-resident memory T cells. Mucosal Immunol. 7:501-510.
39. Schultz, U., W. M. Fitch, S. Ludwig, J. Mandler, and C. Scholtissek. 1991. Evolution of pig influenza viruses. Virology 183:61-73.
40. De Filette, M., W. Fiers, W. Martens, A. Birkett, A. Ramne, B. Löwenadler, N. Lycke, W. M. Jou, and X. Saelens. 2006. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 24:6597-6601.
41. Fan, J., X. Liang, M. S. Horton, H. C. Perry, M. P. Citron, G. J. Heidecker, T. M. Fu, J. Joyce, C. T. Przysiecki, P. M. Keller, et al. 2004. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 22:2993-3003.
42. Fu, T. M., K. M. Grimm, M. P. Citron, D. C. Freed, J. Fan, P. M. Keller, J. W. Shiver, X. Liang, and J. G. Joyce. 2009. Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys. Vaccine 27:1440-1447.
43. Kim, M. C., J. S. Lee, Y. M. Kwon, E. O, Y. J. Lee, J. G. Choi, B. Z. Wang, R. W. Compans, and S. M. Kang. 2013. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection. Antiviral Res. 99:328-335.
44. El Bakkouri, K., F. Descamps, M. De Filette, A. Smet, E. Festjens, A. Birkett, N. Van Rooijen, S. Verbeek, W. Fiers, and X. Saelens. 2011. Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J. Immunol. 186:1022-1031.
45. Kim, M. C., Y. N. Lee, E. J. Ko, J. S. Lee, Y. M. Kwon, H. S. Hwang, J. M. Song, B. M. Song, Y. J. Lee, J. G. Choi, et al. 2014. Supplementation of influenza split vaccines with conserved M2 ectodomains overcomes strain specificity and provides long-term cross protection. Mol. Ther. 22:1364-1374.
46. Kees, U., and P. H. Krammer. 1984. Most influenza A virus-specific memory cytotoxic T lymphocytes react with antigenic epitopes associated with internal virus determinants. J. Exp. Med. 159:365-377.
47. McMichael, A. J., F. M. Gotch, G. R. Noble, and P. A. Beare. 1983. Cytotoxic Tcell immunity to influenza. N. Engl. J. Med. 309:13-17.
48. Ziegler, S. F., F. Ramsdell, and M. R. Alderson. 1994. The activation antigen CD69. Stem Cells 12:456-465.
49. Schön, M. P., A. Arya, E. A. Murphy, C. M. Adams, U. G. Strauch, W. W. Agace, J. Marsal, J. P. Donohue, H. Her, D. R. Beier, et al. 1999. Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice. J. Immunol. 162:6641-6649.
50. Lee, Y. T., J. E. Suarez-Ramirez, T. Wu, J. M. Redman, K. Bouchard, G. A. Hadley, and L. S. Cauley. 2011. Environmental and antigen receptorderived signals support sustained surveillance of the lungs by pathogenspecific cytotoxic T lymphocytes. J. Virol. 85:4085-4094.
51. Slütter, B., L. L. Pewe, S. M. Kaech, and J. T. Harty. 2013. Lung airwaysurveilling CXCR3 (hi) memory CD8 (+) T cells are critical for protection against influenza A virus. Immunity 39:939-948.
52. Ely, K. H., T. Cookenham, A. D. Roberts, and D. L. Woodland. 2006. Memory T cell populations in the lung airways are maintained by continual recruitment. J. Immunol. 176:537-543.
53. Steinert, E. M., J. M. Schenkel, K. A. Fraser, L. K. Beura, L. S. Manlove, B. Z. Igyártó, P. J. Southern, and D. Masopust. 2015. Quantifying Memory CD8 T Cells Reveals Regionalization of Immunosurveillance. Cell 161:737-749.